| This article was first published on les Nouvelles, March 2026 edition. In the high-stakes biotechnology and pharmaceutical industries, and in their emerging offshoots like the fast-growing psychedelics space, patents are both a cornerstone of innovation and a potential latent source of risk. At the heart of this dynamic lie prior art and freedom-to-operate […]
EPO
Understanding Patent Value and Patent Quality
In the last decade and a half patent quality has been at the forefront of debates about patent policy. Industry professionals of all sorts (patent holders, legal practitioners, implementers, policymakers, and academics) seem to agree about the importance of patent quality, but often the consensus stops there. It’s no wonder, because the term ”patent quality” […]
Tipping Point for IP, attests IPBC Conference in Portugal
A very exciting IP global meeting just finished in Portugal, with approximately 500 IP professionals and companies from around the world, and many of the leading figures from the largest IP deals in recent past, USPTO, EPO, academics, politicians and others. IAM did a fantastic job with speakers, logistics, details, as everyone has come to […]